Last reviewed · How we verify

NCT06892418

Impact of Ketoflex 12/3 Diet on Parkinson's Disease Symptoms: A Clinical Study

Completed NA Last updated 2 April 2025
What this trial tests

NA trial testing Ketoflex 12/3 Diet in Parkinson's Disease in 40 participants. Completed in 30 November 2024.

Timeline
30 March 2024
Primary endpoint
30 October 2024
30 November 2024

Quick facts

Lead sponsorIstanbul Medipol University Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment40
Start date30 March 2024
Primary completion30 October 2024
Estimated completion30 November 2024
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Istanbul Medipol University Hospital

Who can join

Adults 40 to 85, any sex, with Parkinson's Disease or Parkinson. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the effects of the Ketoflex 12/3 diet on motor and non-motor symptoms in patients with Parkinson's disease. Participants will follow the Ketoflex 12/3 dietary regimen, and their cognitive function, motor symptoms, sleep patterns, gastrointestinal health, and overall well-being will be assessed through standardized clinical scales. The study will help determine whether a plant-based ketogenic diet combined with intermittent fasting can have a beneficial impact on Parkinson's disease progression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ketoflex 12/3 Diet

Trials testing the same drug.

Other recruiting trials for Parkinson's Disease

Currently open trials in the same condition.

Other Istanbul Medipol University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06892418.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing